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Abstract
Reelin plays an important role in the development and function of the brain and has been linked to different
neuropsychiatric diseases. To further clarify the connection between reelin and psychiatric disorders, we studied the factors
that influence the expression of reelin gene (RELN) and its different isoforms. We examined the total expression of RELN,
allelic expression, and two alternative RELN isoforms in postmortem brain samples from patients with schizophrenia and
bipolar disorder, as well as unaffected controls. We did not find a significant reduction in the total expression of RELN in
schizophrenia or bipolar disorder. However, we did find a significant reduction of the proportion of the short RELN isoform,
missing the C-terminal region in bipolar disorder, and imbalance in the allelic expression of RELN in schizophrenia. In
addition, we tested the association between variation in RELN expression and rs7341475, an intronic SNP that was found to
be associated with schizophrenia in women. We did not find an association between rs7341474 and the total expression of
RELN either in women or in the entire sample. However, we observed a nominally significant effect of genotype-by-sex
interaction on the variation in microexon skipping. Women with the risk genotype of rs7341475 (GG) had a higher
proportion of microexon skipping, which is the isoform predominant in tissues outside the brain, while men had the
opposite trend. Finally, we tested 83 SNPs in the gene region for association with expression variation of RELN, but none
were significant. Our study further supports the connection between RELN dysfunction and psychiatric disorders, and
provides a possible functional role for a schizophrenia associated SNP. Nevertheless, the positive associations observed in
this study needs further replication as it may have implications for understanding the biological causes of schizophrenia and
bipolar disorder.
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Introduction
Reelin, the protein encoded by the RELN gene, is an
extracellular matrix-associated glycoprotein expressed in the
developing brain by Cajal–Retzius cells in the marginal zone of
the cortex and hippocampus and by the cerebellar granule cells in
the in the external granule cell layer. In the adult brain reelin is
most abundant in GABAergic neurons [1,2]. It is involved in
neuronal migration and has been linked to processes of synaptic
plasticity, learning and memory [3]. RELN was initially identified
as the gene mutated in mice with an abnormal reeling gait [4].
Mice lacking the reelin protein have a neuroanatomical defect of
an inverted cortex [5]. Mutations in humans are associated with
an autosomal recessive form of lissencephaly with cerebellar
hypoplasia [6]. Mice heterozygote for the RELN mutation show
subtle behavioral anomalies compared to wild types including a
deficit in pre-pulse inhibition, contextual fear conditioning, social
interaction and social recognition and deficits in learning tasks [7].
The RELN gene contains at least two alternative isoforms that
are conserved across different species suggesting that they are
functionally important [8]. One of them is an alternative splicing
event, involving a microexon of 6 nucleotides long. The inclusion
of the microexon is brain specific. The other isoform is produced
by alternative polyadenylation that results in a truncated protein
lacking the highly basic terminus of the reelin protein [8]. These
two alternative transcripts affect the 39 end part of the RELN gene,
and so they are expected to have a regulatory role on the efficient
activation of downstream signaling [9,10].
Studies of postmortem brain tissues from schizophrenia patients
showed a clear reduction of RELN mRNA and protein levels, of up
to 50% [11,12,13]. A similar reduction is also seen in post-mortem
brains from bipolar patients [14,15]. This reduction of RELN
expression in schizophrenia and bipolar post-mortem brain tissues
was considered among the most consistent molecular findings in
these diseases [16]. However, in different studies the reduction in
reelin was observed in different regions of the brain and was
measured using diverse techniques. Moreover, some have failed to
replicate this reduction [17]. The transcription start site and the
first exon of RELN are GC rich, forming a vast CpG island. The
CpG island offers an optional transcription regulation mechanism
of RELN through DNA methylation of the promoter [18,19]. It
has been proposed that the reduction in reelin expression observed
in psychiatric patients is a consequence of hypermethylation of the
CpG island [20,21], but this observation was not confirmed by
other studies [22,23]. Another potential modifier of RELN
expression is a polymorphic GGC repeat in the gene 5’
untranslated region. This repeat was found to affect RELN
expression in an in-vitro study, using a reporter gene assay [24].
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neuronal migration and synaptic plasticity, led to the hypothesis
that reduced reelin levels may increase susceptibility to psychiatric
disorders, and that reelin is important to the pathogenesis of
schizophrenia [25]. Consistent with this hypothesis, we have
recently reported a genome-wide association of schizophrenia in
an Ashkenazi Jewish (AJ) population that showed a sex-specific
association between an intronic single nucleotide polymorphism
(SNP) in the RELN gene and schizophrenia [26]. We pursued one
SNP (rs7341475) in RELN, showing women-specific association,
because it was approaching genome-wide significance in the first
sample that we genotyped. We were able to replicate the results in
a combined data from four additional populations with an
estimated risk of OR=1.58 (P=8.8610
27; gene-sex interaction:
P=1.6610
25). A follow-up study in another independent sample
of schizophrenia cases and controls from the Ashkenazi Jewish
population replicated the women-specific association with schizo-
phrenia of rs7341475, although with very modest significance
[27]. Furthermore, we used a meta-analysis to test the association
of rs7341475 with schizophrenia by adding the genotype results of
samples published in additional four GWAS of schizophrenia and
excluding the initial discovery sample [28]. The association
between rs7341475 and schizophre+nia in women, after excluding
the data from AJ, was significant (p=9.0610
23), with a calculated
odds ratio (OR) of 1.11, much smaller than the original result. A
recent study that looked at intermediate phenotype measures of
brain structure, brain function, and gene expression, did not find a
significant association with rs7341475 genotypes [29].
To further clarify the connection between RELN and psychiatric
disorders such as schizophrenia and bipolar disorder we studied
the factors that influence the expression of RELN and its different
isoforms. To do so, we used DNA and RNA from the Stanley
Array Collection that includes samples from three diagnostic
groups: schizophrenia, bipolar disorder, and unaffected controls.
Our aims were to identify genetic variants that influence gene
expression or splicing patterns, to try to identify a functional role
for rs7341475, and to test for differences in RELN expression
between cases and controls.
Results
RELN expression in postmortem brains of schizophrenia
and bipolar disorder
We used DNA and RNA that were extracted from the
prefrontal cortex. The samples were from the Stanley Array
Collection, which includes postmortem brain tissues from three
diagnostic groups: schizophrenia, bipolar disorder, and unaffected
controls. We quantified the total and allelic expression of RELN,
an alternative polyadenylation transcript, and alternative splicing
of a microexon. To quantify the total expression of RELN and the
relative expression of the alternative polyadenylation transcript, we
used real-time PCR. On average, 7.8% of transcripts had the
alternative polyadenylation site that resulted in a truncated
protein. To quantify the proportion of the 6-nucleotide microexon
skipping/retention we used PCRs with fluorescent primer and
separated the product on a capillary electrophoresis machine
(Figure 1A, 1B). Peak heights were used to estimate the proportion
of transcripts that retain the microexon. To validate the accuracy
and the linearity of this method, we tested a series of dilutions of
two synthetic oligos that are similar in sequence and length to the
two possible transcripts. A linear relationship (slope=0.98) with
high correlation (R
2=0.99) was observed between the expected
values and the measured proportion calculated from peak heights.
When used with the brain samples, 83.3% of the full length RELN
transcripts retained the microexon. In contrast, the microexon was
completely absent in hepatocellular carcinoma cell line (HepG2;
ATCC HB-8065) that are derived from liver (Figure 1B),
consistent with previous findings that this microexon is brain
specific [8].
We tested the differences in the expression of RELN and its
conserved alternative isoforms between the three diagnosis groups.
In contrast to previous reports, we did not find a significant
reduction in the expression of reelin gene in prefrontal cortex of
schizophrenia or bipolar disorder subjects (F=0.27, df=2,
P=0.76). Correspondingly, non-significant results have been
obtained in the analysis of microarray data of the same samples
(the Stanley Array Collection), as can be seen at the online
genomics database of The Stanley Medical Research Institute
(SMRI). Similarly, the proportion of transcripts missing the
microexon was not significantly different between cases and
controls after controlling for brain PH, which was the most
significant confounding factor (F=12.14, df=1, P=0.00076).
However, the proportion of the alternative polyadenylation
transcript (the short isoform) was significantly different between
the groups (F=5.38, df=2, P=0.0062; Figure 2), being attributed
to lower level of the short transcript in the bipolar disorder group
(6.0%) relative to control (8.5%, F=9.0, df=1, P=0.0040). The
difference between schizophrenia (8.7%) and control samples was
not significant (F=0.064, df=1, P=0.8). The difference between
the bipolar disorder samples and normal controls remained
significant (F=6.52, df=1, P=0.010), after correcting for the
most significant confounding factor (post mortem interval,
F=5.12, df=1, P=0.026). Another expression measure that
showed significant differences between the groups was the level of
allelic expression imbalance (AEI) (Figure 3). We measured the
allelic expression of RELN (i.e. the relative expression of the two
alleles) using a coding SNP (rs2229864) located in exon 50. Only
33 samples were heterozygotes, hence informative for this assay.
The degree of AEI was calculated as the deviation from a balanced
expression. The degree of AEI was different among the diagnostic
groups (F=5.12, df=2, P=0.012), due to a higher level of AEI in
schizophrenia samples (F=7.07, df=1, P=0.015). Six out of eight
informative samples (75%) in the schizophrenia group showed AEI
above 1.2, and three of the samples were above 1.4. In contrast, in
the control and bipolar samples only four out of 25 (16%) were
above 1.2, and none were above 1.4 (Figure 3).
Correlation between RELN expression and genetic
variations
Motivated by the evidence that rs7341475 might increase risk
for schizophrenia, our first aim was to test for correlation between
rs7341475 and RELN expression. After controlling for confound-
ing factors, none of the expression measurements were signifi-
cantly associated with rs7341475 genotypes. However, since the
association between rs7341475 and schizophrenia was restricted to
women, we tested the effect of genotype by sex interaction on the
variation in gene expression. Out of the three expression
measurements, there was a nominal significant effect of genotype
by sex interaction only with the variation in microexon skipping
(F=5.58, df=1, P=0.020; Figure 1C), as a result from an
opposite trend in men and women. On average, men with the GG
genotype showed lower proportion of microexon skipping (15.8%)
than men with AA or AG genotypes (22.6%), whereas in women,
the GG genotype was associated with a higher proportion of
microexon skipping (16.43%) compared to the other genotypes
(14.64%).
To screen for other potential cis-acting variants, we tested 83
SNPs that were within a 1 Mb window centered at the gene. We
Genetic Variation of RELN Expression
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the variations in total RELN expression, the two alternative
isoform and the allelic expression. In addition, we also genotyped
the variable GGC repeats in the gene promoter, that was
previously shown to have a regulatory effect in a reporter gene
expression assay. Similar to a previous report [24], we observed
that the majority of alleles (94.8%) are 8 or 10 triplet repeats. We
also identified four other long and rare alleles with 12–16 GGC
repeats. However, in contrast to the in-vitro study, we did not find
an association between RELN expression and the GGC repeats.
None of the 83 SNPs were significantly associated with variations
in RELN expression, after correcting for multiple tests.
Discussion
Reelin plays an important role in the development and function
of the brain. As such it was the focus of several studies that
examined the variations in the expression of the gene and its
possible connection to neuropsychiatric diseases. In this study, we
examined four different measures of RELN expression: total
expression, allelic expression and two alternative RELN isoforms.
In contrast to some of the previous studies, we did not find a
significant reduction in the total expression of RELN in
postmortem brain samples from patients with schizophrenia or
bipolar disorder, even though the sample size was relatively large.
It should be noted that previous studies measured Reelin mRNA
and protein in several different brain regions and using diverse
methods [11,12,14,15,30]. A previous study that identified a
prefrontal cortex reduction in RELN expression in patients with
schizophrenia and bipolar disorder was performed on a much
smaller sample (15 individuals from each group), that were not
included in the current study [15]. Thus, the different results may
reflect the different methods and samples used in the two studies.
Nonetheless, we had two observations that suggest dysfunction of
reelin in schizophrenia and bipolar disorder. First, we found a
significant reduction of the proportion of the short RELN isoform,
which is caused by an alternative polyadenylation site, in bipolar
disorder samples. Reelin mRNA in the mouse brain consists of 10–
25% of this short isoform, missing the C-terminal region (CTR) of
reelin [8]. The CTR was found to be required for efficient
activation of downstream signaling of reelin [10]. Recently, the
short CTR-lacking isoform of Reelin protein was found to be
present in the developing brain, and to be secreted from neuronal
cells [10]. Although it is clear that the short isoform has a
functional role, we do not know what is cause and consequence of
the reduction in this isoform in bipolar disorder. The second
finding was the imbalance in the allelic expression of RELN in
postmortem brains of schizophrenic patients, but not in controls or
bipolar disorder samples. This finding, although based on a
relatively small sample (subset which were informative), suggests
that the dysregulation of Reelin identified in schizophrenia is
caused by cis-acting factors and not by trans-acting or external
factors that would be expected to influence both alleles equally.
The fact that none of the SNPs in the gene region were associated
with RELN allelic expression may suggest that the allelic
expression imbalance is caused by epigenetic factors. It was
Figure 1. Alternative splicing of microexon (exon #64) in reelin gene. (A) Schematic representation of the last exons of RELN. Boxes are for
exons and lines are for introns (not to scale). The 6-nucleotides microexon (red box) and the alternative polyadenylation site (63A) are shown. The
arrows indicate the positions of PCR primers that were used to measure the alternative splicing of the microexon. The right primer is conjugates to
FAM fluorescent dye (represented as a star) to enable detection with a DNA analyzer. (B) Representative results obtained using this assay with RNA
from liver cells (HEP G2) and from the dorsolateral prefrontal cortex (DLPFC). In liver cells the microexon is completely skipped, while in brain samples
it is mostly retained. (C) The effect of the interaction between rs7341475 genotype and sex on microexon retention. The proportion of microexon
retention was first fitted to the level of brain pH. The residuals from the fitted model are plotted on the Y axis and the genotypes of rs7341475 (GG vs
AG or AA) on the X axis. An opposite trend is seen in men (n=61) and women (n=33): an increase of microexon skipping in women with the GG
genotype and in men with the A bearing genotype.
doi:10.1371/journal.pone.0019955.g001
Genetic Variation of RELN Expression
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e19955recently reported that RELN is imprinted in mouse embryonic
(E15) brains but not in the adult medial prefrontal cortex. In the
embryonic brain, the paternal copy was overexpressed relative to
the maternal copy with a ratio of around 1.7 between the paternal
and maternal alleles [31]. We do not have the parental genotypes
for the samples analyzed in this study; however, one possible
explanation for the observed allelic imbalance of RELN in
schizophrenia might be defects in imprinting erasure in the adult
brain. Since the differences in allelic expression between
schizophrenia and control subjects are based on a small sample,
a further replication study is needed to confirm these results.
Another aim of this study was to test whether rs7341475, an
intronic SNP that was found to be associated with schizophrenia in
women, has any functional effect on RELN expression, and to
identify other potential regulatory cis-acting variants. To explore
the sex-specific genetic effects of rs7341475, we tested the effect of
genotype-by-sex (G6S) interaction on the expression of RELN and
its two conserved isoforms. We found a nominally significant effect
of the G6S interaction on the variation in microexon skipping.
Consistent with the finding of the genome-wide association study,
the risk genotype in women, GG, was associated with higher
proportion of microexon skipping, which is the isoform predom-
inant in tissues outside the brain, and with an opposite trend in
men. However, if the association of the GG genotype with
schizophrenia in women was simply reflected by the higher
proportion of microexon skipping in GG carriers we would expect
a significant protective effect of this genotype on the risk of
schizophrenia in men. Additionally, since we performed several
different tests, this result should be interpreted with caution.
Finally, we tested 83 SNPs in the gene region for association with
expression variation of RELN, but none were significant, which
may be explained by previous studies suggesting a dominant
epigenetic control of RELN expression [18].
In summary, our study further supports the connection between
RELN dysfunction and psychiatric disorders, and provides a
possible functional role for a schizophrenia associated SNP. The
allelic expression imbalance in schizophrenia and the lack of
association between RELN expression and genetic variations,
suggests that cis-acting factors, such as epigenetic mutations or
genetic imprinting defects, are associated with RELN dysfunction
in schizophrenia and possibly other neuropsychiatric disorders.
Additional studies are needed to test the generality of our findings.
Methods and Materials
Human postmortem samples
Samples were obtained from postmortem brains that are
included in the Stanley Array Collection of the Stanley Medical
Research Institute (SMRI). The analyzed sample included 35
individuals with schizophrenia, 32 individuals with bipolar
disorder, and 35 unaffected normal controls. For each individual
we received DNA and RNA that were extracted from the
prefrontal cortex. The experiment was done with coded samples.
The diagnostic status, as well as other clinical variables, was
provided by SMRI only after we completed the expression assays.
The clinical variables included disease status, gender, race, age of
onset, postmortem interval (PMI), brain pH, and total brain
weight. The demographics details for the Stanley Array samples
could be seen at: http://www.stanleyresearch.org/dnn/Portals/
0/Stanley/Array%20Collection%20Demographic%20Details%20
Chat-Final.pdf. In addition, we obtained genotyping results from
Affymetrix SNP 5.0K Array (including 500,000 SNPs) that were
previously performed on the same samples [32]. HepG2 human
hepatoma cell line (ATCC HB 8065) was from the American Type
Figure 2. The proportion of transcripts with alternative
polyadenylation. (A) Schematic representation of the last exons of
RELN (as in Figure 1). The alternative polyadenylation site is located in
an alternative terminal exon (63A), which could be amplified by PCR
with primers as indicated by arrows. (B) The proportion of the short
RELN isoform, missing the C-terminal region of reelin, in brain samples
from bipolar disorder (n=32), normal control (n=35) and schizophrenia
(n=35). The bars heights correspond to the mean proportion of
transcripts with the alternative polyadenylation event; and error bars
are the standard error of the mean. A significant reduction of the
proportion of the short RELN isoform is observed in bipolar disorder
samples (P=0.010).
doi:10.1371/journal.pone.0019955.g002
Figure 3. Allelic expression of RELN in brain samples from
bipolar disorder (n=10), normal control (n=15) and schizo-
phrenia (n=8). Allelic expression was measured six times in each
cDNA sample using a coding SNP (rs2229864). The mean allelic ratio
(major allele frequency divided by minor frequency) for each
informative sample (heterozygote) is presented as a blue diamond.
The red horizontal line is the mean for each diagnostic group. Allelic
expression imbalance is more pronounced in brain samples from
individuals with schizophrenia (P=0.015).
doi:10.1371/journal.pone.0019955.g003
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Committee for the Use of Human Subjects in Research of the
Hebrew University of Jerusalem has reviewed and approved the
research project and waived the need for consent due to the fact
the samples received were collected with consent by the Stanley
Medical Research Institute.
cDNA synthesis
First strand cDNA was generated from around 1 mg of total
RNA using random hexamers and SuperScript III First-Strand
Synthesis System according to the manufacturer’s protocol
(Invitrogen). Contamination by genomic DNA (gDNA) was tested
using PCR amplification across two exons of the beta-catenin
(CTNNB1) gene (primers are listed in Table S1). A larger product
was observed, that included the intron, specifically when tested on
genomic DNA. PCR reactions were carried out in 10 ml volumes
containing 2.5 ml cDNA, 1 ml reaction buffer X10, 1 ml dNTPs
(2 mM), 0.04 ml HotStar Taq polymerase (5 unit/ml, Qiagen) and
0.4 ml of each of the sense and antisense primers (10 mM). The
reaction included pre-incubation at 95uC for 15 min, followed by
40 cycles of 45 sec at 94uC, 60 sec at 55uC, 30 sec at 72uC and
finally, one cycle of 72uC for 5 min. PCR products were separated
on 2% agarose gel.
Real time PCR
Real time PCR in 96-well optical plates (Applied Biosystems)
was used to measure the total expression of reelin, as well as the
proportion of the alternatively polyadenylated transcript (polyA)
(primers are listed in Table S1). Each sample was measured in
triplicates. We used ABI PRISM 7900HT Real-Time PCR
System with the default thermocycler program for all assays:
10 min of pre-incubation at 95uC followed by 40 cycles of 15 sec
at 95uC and one minute at 60uC. Each individual real-time PCR
reaction was in 10 ml volumes containing 2.5 ml cDNA, 5 ml ABI -
Power Cyber Green Mix and 0.4 ml of the sense and antisense
primers (10 mM). The melting curves for each amplicon were
inspected to ensure specific single amplification of the PCR
product. The Cycle threshold (Ct) was setup manually at the level
that reflected the best kinetic PCR parameters. Delta delta Ct
method was used in order to estimate the expression of each gene:
we subtracted the Ct values of the reelin expression from the Ct
values of a reference gene CHL1. CHL1 was selected as a
reference gene as it was showing a similar expression in cases and
controls in previous studies of the same samples using expression
arrays [33]. The delta-Ct value for each sample (based on
triplicates average) represented the relative expression of reelin
gene. Similarly, we calculated the delta-Ct values for the short
alternative polyA transcript by subtracting its Ct values from the
Ct value obtained for the total RELN expression. In order to
determine the efficiency of the PCR amplification, efficiency
curves were generated with a series of six dilutions for each
reaction (RELN efficiency =0.99, CHL1 efficiency =0.95, PolyA
efficiency =0.95).
Quantification of the alternatively spliced microexon
In order to quantify the alternatively spliced microexon, which
is six nucleotides long, we performed a PCR using two primers
flanking the microexon; the sense primer was conjugated with a
fluorescence dye (FAM) (primers are listed in Table S1). PCR
amplification was performed in a 10 ml volume with 2.5 ml cDNA,
2 ml ReadyMix X5 (LAROVA) and 0.4 ml of the sense and
antisense primers. PCR included pre-incubation at 95uC for
2 min, followed by 40 cycles of 15 sec at 94uC, 15 sec at 55uC,
30 sec at 72uC and finally, one cycle of 72uC for 5 min. The PCR
products were separated and quantified on ABI PRISM 3730xl
DNA Analyzer. The proportion of the shorter transcript (lacking
the microexon) was estimated for each sample by relative peak
heights that were obtained from the GeneScan software (Applied
Biosystems). The proportion values were normalized using the log
(base 10) transformation. Each sample was measured in triplicates.
In order to validate the accuracy of our method we tested it with
known ratios of the two possible transcripts. Synthetic oligos
identical by sequence and length to the two amplicons were used
to create different ratios. The two oligos were diluted to
concentration similar to the one in the cDNA and were mixed
in known proportions. The different mixes were amplified by PCR
and read in the same manner as described above for cDNA
samples (measurements were done in triplicates). The proportion
of the shorter oligo was estimated based on the proportion of the
peak heights and compared to the expected proportion.
Genotyping
SNP rs7341475 – We amplified the region containing the SNP
rs7341475 [A/G] by PCR. PCR reactions (10 ml) contained 1 ml
genomic DNA (4 ng/ml), 1 ml reaction buffer X10, 1 ml dNTPs
(2 mM), 0.2 MgCl2 (25 mM), 0.04 ml HotStar Taq polymerase
(5 unit/ml, Qiagen) and 0.625 ml of the sense and antisense
primers mix (8 mM). The reaction included pre-incubation at 95uC
for 15 min, followed by 40 cycles of 60 sec at 94uC, 60 sec at
55uC, 30 sec at 72uC and finally, one cycle of 72uC for 5 min.
PCR products were digested with 1 unit of ApoI (New England
BioLabs) and run in 3% agarose gel resulting in either three
fragments (233+158+30 bp) for the allele A or two fragments
(233+188 bp) for the allele G. SNP rs2229864 was genotyped
using an Allele Specific Primer Extension (ASPE) assay, and
scanned on a BeadXpress reader (Illumina). GGC repeats – we
amplified the region containing the triplet repeat in the reelin gene
by PCR. The sense primer was conjugated with a fluorescence dye
(FAM). PCR amplification was performed in a 10 ml volume with
1 ml genomic DNA (4 ng/ml), 1 ml reaction buffer X10, 1 ml
dNTPs (2 mM), 1 ml DMSO 10%, 0.09 ml HotStar Taq
polymerase (5 unit/ml, Qiagen) and 0.625 ml of the sense and
antisense primers mix (8 mM). We ran the PCR products on ABI
PRISM 3730xl DNA Analyzer. We Used the GeneScan software
(Applied Biosystems) and determined the number of repeats of
alleles by the different fragments sizes.
Allele Specific Expression
We chose the most common coding SNP in RELN. Based on
HapMap (CEU), rs2229864 [C/T] has heterozygosity of 44.4%.
The SNP is located in the fiftieth exon of the gene. We used an
ASPE assay for SNP genotyping using gDNA, as well as for
measuring allelic expression in cDNA. Each cDNA sample was
measured six times. The assay was comprised of 5 main steps:
(1) Amplification of the region containing the measured SNP and
products purification (2) Allele specific primer extension for the
two alleles (3) Hybridization to holographic beads that are unique
for each allele (4) Labeling of the extension sequence (5) Scanning
with a BeadXpress reader. Primers were designed for the ASPE
assay using the online VeraCode assay designer software: two
PCR primers and two ASPE primers. The PCR primers were
designed within exon 50 of the reelin gene flanking the SNP region
in order to enable amplification of both gDNA and cDNA. The
ASPE primers contained one of the alleles [C/T] on the 3’ end of
the sequence. In addition, each ASPE primer had a different
capture sequence of 22 nucleotides that is complementary to the
oligos on a selected VeraCode beads (Illumina). The region
containing the SNP was amplified by PCR with the following
Genetic Variation of RELN Expression
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(for genotyping or allelotyping respectively), 1 ml reaction buffer
X10, 1 ml dNTPs (2 mM), 0.04 ml HotStar Taq polymerase
(5 unit/ml, Qiagen) and 0.4 ml of each of the sense and antisense
primers (10 mM). The reaction included pre-incubation at 95uC
for 15 min, followed by 40 cycles of 45 sec at 94uC, 60 sec at
55uC, 30 sec at 72uC and finally, one cycle of 72uC for 5 min.
PCR products were then purified with 1.34 units of Shrimp
Alkaline Phosphatase (SAP) and 3.4 units of Exonuclease I (Exo I)
and incubated at 37uC for 45 min followed by 15 min at 99uC.
During the ASPE reaction, multiple rounds of primer extension
were performed, with biotinylated dCTP incorporated into the
extension products. Individual ASPE reactions were carried out in
10 ml volume. Each reaction contained 1 ml reaction buffer (X10),
0.5 ml 3 nucleotides mix (dATP,dTTP and dGTP, 100 mM),
0.125 ml biotin 14-dCTP (400 mM), 0.5 ml ASPE primer mix
(5 mM, see sequence bellow), 0.1 ml HotStar Taq polymerase
(5 Units /ml, Qiagen) and 1.5 ml purified PCR products from the
previous step. ASPE reaction included pre-incubation at 95uC for
15 min, followed by 30 cycles of 45 sec at 95uC, 60 sec at 55uC,
30 sec at 72uC. VeraCode beads were kitted into 96-well
polypropylene plates (Corning). 8 ml of the ASPE products were
transferred into the bead-kitted plate and hybridized with the
matching beads. The biotinylated extension products were labeled
with streptavidin-Alexa Fluor 647 (Invitrogen). The labeled beads
were scanned using a BeadXpress reader.
Data analysis
Data analysis was performed using the R language and
environment for statistical computing (http://www.r-project.org/).
Expression data was tested for normal distribution using Shapiro-
Wilk normality test. The proportion of microexon skipping and the
delta Ct values were normalized using a log transformation.
Analysis of Variance (ANOVA) was used to test for differences
between the three diagnostic groups, after controlling for significant
confounding variables. For analyzing the allelic expression
imbalance, we calculated the absolute difference of the proportion
of T allele in cDNA from the expected balanced proportion in
gDNA. To account for systematic shift in the proportion of the T
allele with increase in intensity, we fitted a linear regression model
and estimated the slope and intercept for the proportions in gDNA.
The expected proportion value for the cDNA was calculated based
on this linear model. To test the association between SNPs and
expression measurements, we selected SNPs that were in Hardy-
Weinbergequilibrium(P,0.05/numberofSNPs),andwithaminor
allele frequency above 5%. Homozygote calls were combined with
heterozygotes, if the number of homozygotes was equal or lower
than five. To test for association between SNPs and allelic
expression, we combined the two homozygotes groups together
and tested the differences in the allelic expression imbalance for
eachSNP between heterozygotes and homozygotes. As we tested83
different SNPs, we corrected for multiple testing by a permutation
test. In the permutation test the expression values were randomly
distributed among the subjects, whereas the SNPs distribution was
unchanged. We ran the permutations until we observed more than
20 instances with a P-value equal or lower than the minimum
observed P-value. The corrected P-value was calculated as 20
divided by the number of permutations.
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